Araştırma Makalesi
BibTex RIS Kaynak Göster

Kadınlarda Kadınlarda Menopoz Belirtilerinin Aile Planlaması Yöntemi Tercihlerine Etkisi: Kesitsel Bir ÇalışmaTercihlerine Etkisi: Kesitsel Bir Çalışma

Yıl 2022, Cilt: 2 Sayı: 2, 183 - 198, 29.12.2022

Öz

Amaç: Tanımlayıcı, kesitsel tipte olan bu araştırma, kadınların premenopozal dönemde yaşadıkları menopoz semptomlarının aile planlaması yöntemi tercihlerine etkisini belirlemek amacıyla tasarlanmıştır. Gereç ve Yöntemler: Türkiye'de bir hastaneye kayıtlı kadınlar (n=280) 1 Kasım-1 Mayıs 2020 tarihleri arasında Bireysel Tanımlama Formu ve Menopoz Derecelendirme Ölçeği'ni yanıtladı. Veriler yüzde, sayı, ortalama analizleri kullanılarak değerlendirildi. , standart sapma, Kruskal Wallis testi ve Pearson korelasyon analizi. Bulgular: Araştırmaya katılan kadınların %74,2'sinin aile planlaması yöntemlerinden herhangi birini kullandığı ve bu yöntemler incelendiğinde en çok bakır rahim içi araç (%18,9), geri çekme yöntemi (%14,6), sırasıyla tuballigasyon (%13,2), kondom (%10,7), hap/kombine oral kontraseptifler (%9,6). Menopoz Derecelendirme Ölçeği toplam puanı 17.51 ± 7.00 iken, aile planlaması yöntemi kullanmayan kadınlarda (19.55 ± 5.75), geri çekme (18.26 ± 7.00) ve oral kontraseptif kombine kullanan kadınlarda (18.25) daha yüksek bulundu. ±5.64) yöntemler. Sonuç: Çalışmamıza katılan premenopozal dönemdeki kadınların çoğunluğu herhangi bir aile planlaması yöntemi ile korunmuştur. Vazomotor semptomları olan kadınlar menopoza girdiklerini düşünerek aile planlaması kullanmayı bırakmışlardır. Aile planlaması kullananlar semptomları azaltmak için kombine oral konseptif yöntemini tercih ettiler.

Kaynakça

  • 1. Bateson D, McNamee K. (2017). Perimenopausal contraception: A practice-based approach. AFP. 6(46): 372-377.
  • 2. Bella JD et al. (2016). Contraception and family planning at the extreme of reproductive life – climacteric. Rev. Assoc. Med. Bras. 5(62):120-135. https://doi.org/10.1590/1806-9282.62.05.454.
  • 3. Bakour SH et al. (2017). Contraceptive methods and issues around the menopau se:an evidence update. DFSRH MRCOG. 19: 289–97. doı: 10.1111/tog.12416The Obstetrician & Gynaecologisthttp://onlinetog.org.
  • 4. Faculty of Sexual & Reproductive Healthcare (FSRH). (2017). Guideline contraception for women aged over 40 years. 2017. https://www.fsrh.org/standards-and-guidance/documents/fsrh-guidance-contraception-for-women-aged-over-40-years-2017.
  • 5. Kelsey B. (2012). Contraception for women over 40. Nurse Pract 2012; 37(6):40-5.
  • 6. Batur P, Megan C. McNamara A. (2015). Contraception for the perimenopausal woman: What’s best?. The Journal of Family Practice. 11(64): 134-144. 7. Linton A, Golobof A, Shulman LP. (2016). Contraception for the perimenopausal woman. Climacteric. Climacteric journal. 19(6): 526-534.
  • 8. Cho MK. (2018).Use of combined oral contraceptives in perimenopausal women. Chonnam Med J. 54:153-158. https://doi.org/10.4068/cmj.2018.54.3.153. 9. Turkey Demographic and Health Surveys. (2018). Population and Health Research 2018. http://www.hips.hacettepe.edu.tr/tnsa2013/report /TDHS_2018_main_repor.pdf. 2018.
  • 10. Baldwin MK, Jensen JT. (2013). Contraception during the perimenopause. Maturitas. 76: 235-42. doı: 10.1016/j.maturitas.2013.07.009.
  • 11. Scheineder HP, Heinemann LAJ, Rosemeier HP, Potthoff P, Behre HM. (2000). The Menapouse Rating Scale (MRS) comparison with kupperman index and quality of life scale SF-36, Climacteric 2000; 3(1): 50-8.
  • 12. Gürkan CO. (2005). Reliability and validity of the Turkish forum of menopause symptoms assessment scale. Journal of Nursing Forum 2005; 30 (5) .101-113.
  • 13. Solanke BL. (2017). Factors influencing contraceptive use and non-use among women of advanced reproductive age in Nigeria. J Health Popul Nutr 2017; 36: 1-12. doi: 10.1186/s41043-016-0077-6.
  • 14. Bitzer J. (2019). Overview of perimenopausal contraception Climacteric 2019; 22:1; 44-50. doi: 10.1080/13697137.2018.1540566.
  • 15. Panay N and Fenton A. Perimenopausal hormonal contraception – can we do better? Pages 2014; 23: 517-519. doi.org/10.3109/13697137.2014.955446.
  • 16. NA Kailas, Sifakis S, Koumantakis E. (2004). Contraception during perimenopause. The Eurapan Journal of Contraception and Reproductive Health Care. 2004; 24; 19-25. https://doi.org/10.1080/13625180400020861.
  • 17. Pınar G. (2011). Contraseptive use and unmet need for contraception in perimenopausal women. Medical Sciences 2011; 6(1): 1-8.
  • 18. Doğru HY, Oktay G, İşgüder ÇK, Özsoy AZ, Çakmak B, Delibaş İB, Yıldız NÇ. (2016). Women's views on family planning by age groups and evaluation of their chosen methods: Tertiary single center experience. Dicle Medical Journal 2016; 43 (3): 413-418. doi: 10.5798 / diclemedj.0921.2016.03.0706 413.
  • 19. Cumming GP, Cochrane R, Currie HD, Moncur R, Lee AJ. (2012). Web-based survey 'Contraception and attitudes to sexual behaviour' completed by women accessing a UK menopause website. Menopause Int. 2012; 18(3): 106-9. doi: 10.1258/mi.2012.012020. Epub 2012 Jul 3.
  • 20. Lader D. (2009). Opinions survey report No. 41: contraception and sexual health 2008/09. Richmond: Office for National Statistics 2009; 1: 1-12.
  • 21. Türk R, Terzioğlu F. (2012). Wıthdrawal method and the affecting factors of it use. Ankara Journal of Health Sciences 2012; 1 (3): 67-80.

The Effect of Menopause Symptoms on Family Planning Method Preferences in Women: A Cross-Sectional Study

Yıl 2022, Cilt: 2 Sayı: 2, 183 - 198, 29.12.2022

Öz

Objective: This descriptive, cross-sectional study examined was designed to determine the effect of menopausal symptoms experienced by women in the premenopausal period on family planning method preferences. Material and Methods: Women (n = 280) registered at a hospital in Turkey responded to a The Individual Identification Form and the Menopause Rating Scale between November 1 and May 1, 2020. The data were evaluated using the analyses of percentage, number, mean, standard deviation, Kruskal Wallis test and Pearson correlation analysis. Results: It was determined that 74.2% of the women who participated in the study used any of the family planning methods, and when these methods were examined, they mostly used the copper intrauterine device (18.9%), withdrawal method (14.6%), tuballigation (13.2%), condom (10.7%), pill/combined oral contraceptives (9.6%) respectively. While Menopause Rating Scale total score was 17.51 ± 7.00, it was found to be higher in women who did not use any family planing method (19.55 ± 5.75) and in women who used the withdrawal (18.26 ± 7.00) and combine oral contraceptives (18.25±5.64) methods. Conclusion: The majority of women in the premenopausal period who participated in our study were protected by any family planing method. Women with vasomotor symptoms stopped using family planing considering that they entered the menopause. Those using family planing preferred the combine oral contaceptives method in order to reduce the symptoms.

Kaynakça

  • 1. Bateson D, McNamee K. (2017). Perimenopausal contraception: A practice-based approach. AFP. 6(46): 372-377.
  • 2. Bella JD et al. (2016). Contraception and family planning at the extreme of reproductive life – climacteric. Rev. Assoc. Med. Bras. 5(62):120-135. https://doi.org/10.1590/1806-9282.62.05.454.
  • 3. Bakour SH et al. (2017). Contraceptive methods and issues around the menopau se:an evidence update. DFSRH MRCOG. 19: 289–97. doı: 10.1111/tog.12416The Obstetrician & Gynaecologisthttp://onlinetog.org.
  • 4. Faculty of Sexual & Reproductive Healthcare (FSRH). (2017). Guideline contraception for women aged over 40 years. 2017. https://www.fsrh.org/standards-and-guidance/documents/fsrh-guidance-contraception-for-women-aged-over-40-years-2017.
  • 5. Kelsey B. (2012). Contraception for women over 40. Nurse Pract 2012; 37(6):40-5.
  • 6. Batur P, Megan C. McNamara A. (2015). Contraception for the perimenopausal woman: What’s best?. The Journal of Family Practice. 11(64): 134-144. 7. Linton A, Golobof A, Shulman LP. (2016). Contraception for the perimenopausal woman. Climacteric. Climacteric journal. 19(6): 526-534.
  • 8. Cho MK. (2018).Use of combined oral contraceptives in perimenopausal women. Chonnam Med J. 54:153-158. https://doi.org/10.4068/cmj.2018.54.3.153. 9. Turkey Demographic and Health Surveys. (2018). Population and Health Research 2018. http://www.hips.hacettepe.edu.tr/tnsa2013/report /TDHS_2018_main_repor.pdf. 2018.
  • 10. Baldwin MK, Jensen JT. (2013). Contraception during the perimenopause. Maturitas. 76: 235-42. doı: 10.1016/j.maturitas.2013.07.009.
  • 11. Scheineder HP, Heinemann LAJ, Rosemeier HP, Potthoff P, Behre HM. (2000). The Menapouse Rating Scale (MRS) comparison with kupperman index and quality of life scale SF-36, Climacteric 2000; 3(1): 50-8.
  • 12. Gürkan CO. (2005). Reliability and validity of the Turkish forum of menopause symptoms assessment scale. Journal of Nursing Forum 2005; 30 (5) .101-113.
  • 13. Solanke BL. (2017). Factors influencing contraceptive use and non-use among women of advanced reproductive age in Nigeria. J Health Popul Nutr 2017; 36: 1-12. doi: 10.1186/s41043-016-0077-6.
  • 14. Bitzer J. (2019). Overview of perimenopausal contraception Climacteric 2019; 22:1; 44-50. doi: 10.1080/13697137.2018.1540566.
  • 15. Panay N and Fenton A. Perimenopausal hormonal contraception – can we do better? Pages 2014; 23: 517-519. doi.org/10.3109/13697137.2014.955446.
  • 16. NA Kailas, Sifakis S, Koumantakis E. (2004). Contraception during perimenopause. The Eurapan Journal of Contraception and Reproductive Health Care. 2004; 24; 19-25. https://doi.org/10.1080/13625180400020861.
  • 17. Pınar G. (2011). Contraseptive use and unmet need for contraception in perimenopausal women. Medical Sciences 2011; 6(1): 1-8.
  • 18. Doğru HY, Oktay G, İşgüder ÇK, Özsoy AZ, Çakmak B, Delibaş İB, Yıldız NÇ. (2016). Women's views on family planning by age groups and evaluation of their chosen methods: Tertiary single center experience. Dicle Medical Journal 2016; 43 (3): 413-418. doi: 10.5798 / diclemedj.0921.2016.03.0706 413.
  • 19. Cumming GP, Cochrane R, Currie HD, Moncur R, Lee AJ. (2012). Web-based survey 'Contraception and attitudes to sexual behaviour' completed by women accessing a UK menopause website. Menopause Int. 2012; 18(3): 106-9. doi: 10.1258/mi.2012.012020. Epub 2012 Jul 3.
  • 20. Lader D. (2009). Opinions survey report No. 41: contraception and sexual health 2008/09. Richmond: Office for National Statistics 2009; 1: 1-12.
  • 21. Türk R, Terzioğlu F. (2012). Wıthdrawal method and the affecting factors of it use. Ankara Journal of Health Sciences 2012; 1 (3): 67-80.
Toplam 19 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Kadın Araştırmaları
Bölüm Araştırma Makaleleri
Yazarlar

Saadet Boybay Koyuncu 0000-0002-6145-9179

Mehmet Bülbül 0000-0001-5695-2586

Yayımlanma Tarihi 29 Aralık 2022
Gönderilme Tarihi 4 Ekim 2022
Yayımlandığı Sayı Yıl 2022 Cilt: 2 Sayı: 2

Kaynak Göster

APA Boybay Koyuncu, S., & Bülbül, M. (2022). The Effect of Menopause Symptoms on Family Planning Method Preferences in Women: A Cross-Sectional Study. Ondokuz Mayıs Üniversitesi Kadın Ve Aile Araştırmaları Dergisi, 2(2), 183-198.

ONDOKUZ MAYIS ÜNİVERSİTESİ
Kadın ve Aile Çalışmaları Uygulama ve Araştırma Merkezi Yayınıdır.
SAMSUN